On 2 February 2022 the European Commission presented a new Standardisation Strategy. The goal of the strategy is to strengthen the EU’s competitiveness by setting better standards that can, amongst other things, foster innovation.
This is relevant for the in silico community because the strategy proposes five key actions, one of which is to “anticipate, prioritise and address standardisation needs in strategic areas.”
As Avicenna Alliance working group continues to call for harmonisation and global standards for in silico medicine, this recognition of the importance of standards for research and innovation provides additional evidence as to the need for best simulation practices. The working group members will continue to monitor this strategy and identify any opportunities to engage with it.